ArticleBMC infectious diseases2025
Evaluation of Triglyceride-Glucose (TyG) index in individuals living with HIV under antiretroviral therapy (ART).
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionFasting triglyceride-glucose (TyG) index, which indirectly evaluates insulin resistance, is an important risk parameter in various diseases, especially cardiovascular diseases (CVD). There are very limited number of studies evaluating TyG index in individuals living with HIV, where the incidence of these diseases is increased. This study was conducted to determine the change in TyG index during the first year of antiretroviral therapy and the relationship between TyG index and CD4/CD8 ratio.
methodsData of patients living with HIV who were followed up between 2011 and 2024 were retrospectively analyzed. 343 ART-naive, non-diabetic patients who completed their first year of follow-up under ART were included in the study. TyG index was calculated according to the formula Ln [fasting triglyceride (mg/dL) x fasting glucose (mg/dL)/2]. Patients with TG values >150 mg/dl at the time of diagnosis constituted the hypertriglyceridemic (HTG) group, and patients with TG values ≤150 mg/dl at the time of diagnosis constituted the non-hypertriglyceridemic (NHTG) group.
resultsHypertriglyceridemia was detected in 143 (42%) of our patients in the initial evaluation at the time of diagnosis. No correlation was found between TyG index and lymphocyte subgroups at the time of diagnosis (p > 0.05). However, a positive linear correlation was found between TyG index and CD4 + and CD8 + T cell counts (r = 0.073, p = 0.035; r = 0.181, p < 0.001, respectively) during the first year of ART. TyG index did not show any significant change in the months after starting ART in the NHTG group, while it decreased statistically significantly in the HTG group (p < 0.001).
conclusionThe decrease in TyG index with control of immune activation under ART is promising as an important follow-up parameter. Therefore, data from new prospective studies are needed to analyze conditions such as CVD and metabolic syndrome that will occur in the longer term under ART.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.